Macfarlanes has advised Cera Care on a $150m debt and equity funding round led by BDT & MSD Partners and Schroders Capital to support future growth. 

Cera is one of the UK’s largest and fastest growing Healthtech businesses, harnessing AI to deliver home healthcare with the aim of driving improved care and outcomes for patients and cost-efficiency for the NHS.  

Co-founded in 2016 by Dr Ben Maruthappu MBE, who was named EY’s ‘UK Entrepreneur of the Year’ in 2024, Cera was awarded the “Tech for Good Prize” at the UK Tech Awards 2024 and featured in The Sunday Times “Tech 100 2025”.  The business operates in the UK and Germany, has raised over $400m in equity and debt including the latest investment by BDT & MSD and Schroders, and has enjoyed outstanding growth since it launched – now the UK’s largest HealthTech company and one of Europe’s fastest-growing businesses, with a 5-year CAGR of 150%.

Dr Ben Maruthappu MBE, founder and chief executive of Cera, said: “Cera is revolutionising healthcare using technology, AI and data – improving and saving countless lives nationwide, rebuilding the healthcare workforce and reducing NHS pressures.  We are deeply grateful to our partners for their support; this funding round will accelerate our impact and our transformation of healthcare.”

The Macfarlanes team was led by finance Partner Kirstie Hutchinson with assistance from Senior Counsel Pinar Celebi, Senior Associate Xian Wei Yeo and Associate Will Underwood.  Corporate and M&A advice was provided by Partner Stephen Pike and Consultant Will David. Tax advice was provided by Partner Jeremy Moncrieff, Senior Counsel Shaul Steinberg and Associate Luke Silverman.